SELECTA BIOSCIENCES INC (SELB) Stock Price, Forecast & Analysis
USA - NASDAQ:SELB - US8162121045 - Common Stock
SELB Key Statistics, Chart & Performance
The current stock price of SELB is 0.8812 USD. In the past month the price decreased by -21.32%. In the past year, price decreased by -37.06%.
SELB Latest News, Press Relases and Analysis
SELB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About SELB
Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
Company Info
SELECTA BIOSCIENCES INC
65 Grove Street
Watertown MASSACHUSETTS 02472 US
CEO: Carsten Brunn
Employees: 58
Phone: 16179231400.0
SELECTA BIOSCIENCES INC / SELB FAQ
What does SELB do?
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
Can you provide the latest stock price for SELECTA BIOSCIENCES INC?
The current stock price of SELB is 0.8812 USD. The price decreased by -8% in the last trading session.
Does SELECTA BIOSCIENCES INC pay dividends?
SELB does not pay a dividend.
How is the ChartMill rating for SELECTA BIOSCIENCES INC?
SELB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for SELB stock?
12 analysts have analysed SELB and the average price target is 3.57 USD. This implies a price increase of 305.13% is expected in the next year compared to the current price of 0.8812.
How many employees does SELECTA BIOSCIENCES INC have?
SELECTA BIOSCIENCES INC (SELB) currently has 58 employees.
Can you provide the market cap for SELECTA BIOSCIENCES INC?
SELECTA BIOSCIENCES INC (SELB) has a market capitalization of 135.20M USD. This makes SELB a Micro Cap stock.
SELB Technical Analysis
SELB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SELB. SELB has a bad profitability rating. Also its financial health evaluation is rather negative.
SELB Financial Highlights
Over the last trailing twelve months SELB reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS decreased by -237.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.12% | ||
| ROE | -53.55% | ||
| Debt/Equity | 0.21 |
SELB Forecast & Estimates
12 analysts have analysed SELB and the average price target is 3.57 USD. This implies a price increase of 305.13% is expected in the next year compared to the current price of 0.8812.
For the next year, analysts expect an EPS growth of -228.11% and a revenue growth -72.53% for SELB